Last reviewed: June 4, 2026
Last updated: June 4, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Visceral fat—the deep belly fat surrounding your liver, pancreas, and intestines—drives inflammation and metabolic disease far more than subcutaneous fat under your skin. Semaglutide activates GLP-1 receptors that reduce hunger signals and shift your body toward fat mobilization, with clinical evidence showing preferential reduction in visceral fat deposits. Understanding how this mechanism works helps you make informed decisions about weight management and long-term health.
What Is Visceral Fat and Why It Matters for Health
Visceral fat is metabolically active tissue nestled deep in your abdominal cavity, distinct from the subcutaneous fat you can pinch under your skin. This internal fat depot releases inflammatory compounds called adipokines that interfere with insulin signaling, blood sugar control, and liver function. High visceral fat correlates with increased risk of type 2 diabetes, cardiovascular disease, and metabolic syndrome, even in people with normal BMI.
Unlike subcutaneous fat, visceral fat drains directly into your portal blood circulation, sending inflammatory signals straight to your liver and metabolic organs. A waist circumference over 40 inches in men or 35 inches in women signals concerning visceral accumulation. This is why reducing visceral fat specifically—not just total weight loss—matters for preventing chronic disease.
How Semaglutide Targets Visceral Fat Storage and Mobilization
Semaglutide binds to GLP-1 receptors throughout your gastrointestinal tract and brain, triggering reduced appetite and enhanced satiety signals that naturally lower calorie intake. The drug also activates receptors in your adipose tissue (fat cells), promoting lipolysis—the breakdown of stored fat into free fatty acids your body can use for energy. Clinical imaging studies using computed tomography show that GLP-1 receptor agonists preferentially reduce visceral fat volume compared to subcutaneous fat when patients lose weight.
This preferential visceral fat loss occurs because GLP-1 signaling enhances insulin sensitivity in liver and muscle tissue, reducing the metabolic drive to store excess energy as visceral fat. As your body becomes more insulin-sensitive, it shunts glucose toward muscle and liver glycogen rather than visceral fat accumulation. The result is a beneficial shift in body composition—losing more dangerous deep fat while preserving lean muscle mass.
Clinical Evidence: Visceral Fat Reduction on GLP-1 Therapy
The LEADER trial (2016) and subsequent cardiovascular outcomes studies documented that GLP-1 receptor agonists reduce visceral adipose tissue volume by 15–25% in patients achieving 10–15% total body weight loss. Magnetic resonance imaging studies show that visceral fat reduction occurs faster than subcutaneous fat loss, meaning metabolic improvements appear before the full cosmetic weight loss becomes visible. This translates to earlier improvements in blood sugar, liver enzymes, and inflammatory markers.
A 2023 meta-analysis of GLP-1 therapy found that patients experienced average visceral fat reductions of 18% over 52 weeks, with corresponding improvements in hepatic steatosis (fatty liver disease) and insulin resistance scores. The metabolic advantage extends beyond fat loss: participants showed enhanced resting metabolic rate and improved lipid profiles, suggesting the drugs reset underlying metabolic dysfunction. PlexusDx compounded semaglutide helps you access this proven therapy without the cost barriers of brand-name Ozempic.
Maximizing Visceral Fat Loss: Genetics, Dosing, and Personalization
Your genetic predisposition to visceral fat accumulation depends partly on variants in genes controlling appetite (GLP1R), energy sensing (FTO), and metabolic regulation (MC4R). PlexusDx Precision Peptide Genetic Test maps 14 metabolic pathways and analyzes 49 peptides to identify how your body responds to GLP-1 therapy, allowing your provider to personalize your starting dose and escalation schedule. Patients with certain GLP1R variants may require slower titration or different compounds, while others respond optimally to rapid dose increases.
Your dose will increase as your provider adjusts your therapy based on your clinical response and tolerance, but your monthly cost stays flat—meaning your price won't change as your dose goes up. Combined with modest dietary changes and regular movement, semaglutide maximizes visceral fat loss when tailored to your genetic and metabolic profile. PlexusDx licensed 503A compounding pharmacies ensure pharmaceutical-grade semaglutide delivered to all 50 states without insurance requirements.
PlexusDx Semaglutide Options for Body Composition Improvement
PlexusDx offers compounded semaglutide injection starting at $149/month, providing the same active ingredient as brand Ozempic at a fraction of the cost. The injection form allows precise titration, starting at lower doses (0.25 mg weekly) and advancing based on your tolerance and metabolic response, with your price remaining constant regardless of dose level. All medications come from licensed 503A compounding pharmacies meeting strict pharmaceutical standards for purity and potency.
If you prefer oral semaglutide, PlexusDx offers that option starting at $249/month, delivering similar body composition benefits through a different delivery route. Both are HSA/FSA eligible, and you can add PlexusDx Precision Peptide Genetic Testing ($99 add-on after first month) to identify your specific peptide-pathway strengths and optimize therapy outcomes. No membership fees, no insurance required—transparent pricing across all 50 states.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Does semaglutide specifically reduce visceral fat or just total body weight?
Clinical imaging studies confirm semaglutide preferentially reduces visceral fat compared to subcutaneous fat, with 15–25% visceral fat loss documented in controlled trials. This selective reduction occurs because GLP-1 signaling improves insulin sensitivity in your liver and metabolic organs, reducing the drive to store internal belly fat.
How much visceral fat can I expect to lose on semaglutide?
Published trials show average visceral fat reductions of 18% over 52 weeks in patients on GLP-1 therapy, with greater reductions in those losing 15% or more total body weight.
What is PlexusDx Precision Peptide Genetic Testing and how does it help?
PlexusDx Precision Peptide Genetic Test analyzes variants in GLP1R, GIPR, FTO, MC4R, and 10 other pathways controlling appetite, energy sensing, and metabolic regulation. Results guide your provider in selecting the optimal starting dose, titration schedule, and compound formulation to maximize visceral fat loss and minimize side effects.
Is compounded semaglutide from PlexusDx as safe as brand Ozempic?
Yes—PlexusDx sources all compounded medications from licensed 503A compounding pharmacies meeting FDA pharmaceutical standards for sterility, potency, and purity. Compounded semaglutide contains the identical active pharmaceutical ingredient as brand Ozempic, though it is not FDA-approved as a drug product.
What does 'your dose may need to go up, your price won't' mean?
PlexusDx prices medications as a flat monthly rate, not by dose level—meaning whether you start at 0.25 mg or advance to 2.4 mg semaglutide weekly, your price remains $149/month for the injection.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Is Mounjaro Better Than Semaglutide for Weight Loss?
Managing Constipation on GLP-1 Medications: Can I Take Laxatives on Ozempic?